TY - JOUR T1 - Optimal Allocation of COVID-19 Test Kits Among Accredited Testing Centers in the Philippines JF - medRxiv DO - 10.1101/2020.04.14.20065201 SP - 2020.04.14.20065201 AU - Christian Alvin H. Buhat AU - Jessa Camille C. Duero AU - Edd Francis O. Felix AU - Jomar F. Rabajante AU - Jonathan B. Mamplata Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/17/2020.04.14.20065201.abstract N2 - Testing is crucial for early detection, isolation, and treatment of coronavirus disease (COVID-19)-infected individuals. However, in resource-constrained countries such as the Philippines, test kits have limited availability. As of 12 April 2020, there are 11 testing centers in the country that have been accredited by the Department of Health (DOH) to conduct testing. In this paper, we determine the optimal percentage allocation of COVID-19 test kits among accredited testing centers in the Philippines that gives an equitable chance to all infected individuals to be tested. Heterogeneity in testing accessibility, population density of municipalities, and the capacity of testing facilities are included in the model. Our results showed that the range of optimal allocation per testing center are: Research Institute for Tropical Medicine (4.17% −6.34%), San Lazaro Hospital (14.65% −24.03%), University of the Philippines-National Institutes of Health (16.25% −44.80%), Lung Center of the Philippines (15.8% −26.40%), Baguio General Hospital Medical Center (0.58% −0.76%), The Medical City, Pasig City (5.96% −25.51%), St. Luke’s Medical Center, Quezon City (1.09% −6.70%), Bicol Public Health Laboratory (0.06% −0.08%), Western Visayas Medical Center (0.71% −4.52%), Vicente Sotto Memorial Medical Center (1.02% −2.61%), and Southern Philippines Medical Center (≈0.01%). If there will be changes in the number of testing centers, our model can still be used to modify the test kit allocation. Our results can serve as a guide to the authorities in distributing the COVID-19 test kits. These can also be used to determine the capacity of testing centers and the effects of increasing its number. The model can also be used for proposing additional number and location of new testing centers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo specific funding was used for this work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and program used are available online at: https://github.com/alvinizer/optimalallocationPH https://github.com/alvinizer/optimalallocationPH ER -